Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, open label, multicenter, efficacy and safety study of several infusions of Promethera HepaStem in Urea Cycle Disorders pediatric patients

Trial Profile

A prospective, open label, multicenter, efficacy and safety study of several infusions of Promethera HepaStem in Urea Cycle Disorders pediatric patients

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 25 Jul 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesenchymal stem cell therapy (Primary)
  • Indications Argininosuccinic aciduria; Inborn urea cycle disorders
  • Focus Therapeutic Use
  • Sponsors Promethera Biosciences
  • Most Recent Events

    • 22 Jul 2022 Status changed from recruiting to completed.
    • 05 Oct 2021 This trial has been completed in Poland, according to European Clinical Trials Database record. (2019-08-01)
    • 23 Jan 2021 This trial has been completed in Belgium and France, according to European Clinical Trials Database record. (Global end date:2019-08-01)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top